Full-Time
Develops biologic therapies for serious illnesses
No salary listed
Mid, Senior
Hyderabad, Telangana, India
Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's approach involves a strong commitment to research and development, allowing them to create new treatments and maintain a pipeline of potential therapies. Unlike many competitors, Amgen emphasizes biologic therapies and reinvests a large portion of its earnings back into R&D. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Conference Attendance Budget
The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.
Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim
JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.
Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]
The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.